Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778
administered twice daily for 84 days in subjects with macular edema due to RVO.